Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 PET Imaging in Head and Neck Cancer and Brain Metastases
NCT05408871Phase 1Terminated
- Sponsor
- Yale University
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-BMS-986192 in head and neck squamous cell carcinoma (HNSCC) and brain metastases (2 arms), sponsored by Yale University. Primary endpoint: Non-invasive quantitative PD-L1 levels (VT). Started Feb 2023; status: terminated.
02
Drugs
18F-BMS-986192
03
Conditions
head and neck squamous cell carcinoma (HNSCC)brain metastases
Beyond the preview
Go deeper on NCT05408871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408871.